Olema Pharmaceuticals, Inc.

NASDAQ

Market Cap.

312.75M

Avg. Volume

970.79K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. News

Olema Pharmaceuticals, Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
olema.com

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals, Inc. Earnings & Revenue

Olema Pharmaceuticals, Inc. Financials

Table Compare

Compare OLMA metrics with:

   

Earnings & Growth

OLMA

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

OLMA

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

OLMA

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

OLMA

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Olema Pharmaceuticals, Inc. Income

Olema Pharmaceuticals, Inc. Balance Sheet

Olema Pharmaceuticals, Inc. Cash Flow

Olema Pharmaceuticals, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioBuy
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Olema Pharmaceuticals, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

Olema Pharmaceuticals, Inc. Executives

NameRole
Dr. Sean P. Bohen M.D., Ph.D.President, Chief Executive Officer & Director
Mr. Shane William Charles Kovacs M.B.A.Chief Operating & Financial Officer
Dr. Naseem Zojwalla M.D.Chief Medical Officer
Dr. David C. Myles Ph.D.Chief Discovery & Non-Clinical Development Officer
Ms. Julie DexterSenior Vice President & Head of People
NameRoleGenderDate of BirthPay
Dr. Sean P. Bohen M.D., Ph.D.President, Chief Executive Officer & Director19671.12M
Mr. Shane William Charles Kovacs M.B.A.Chief Operating & Financial OfficerMale1974845.37K
Dr. Naseem Zojwalla M.D.Chief Medical Officer1973777.97K
Dr. David C. Myles Ph.D.Chief Discovery & Non-Clinical Development Officer1963200K
Ms. Julie DexterSenior Vice President & Head of PeopleFemale

--

Olema Pharmaceuticals, Inc. Insider Trades

Date28 Feb
NameMyles David C.
RoleCH. DISCOV. & NON-CLIN DEV OFF
TransactionAcquired
TypeA-Award
Shares205000
Date28 Feb
NameZojwalla Naseem
RoleCHIEF MEDICAL OFFICER
TransactionAcquired
TypeA-Award
Shares205000
Date28 Feb
NameMitchell Shawnte
RoleCHIEF LEGAL OFFICER
TransactionAcquired
TypeA-Award
Shares450000
Date28 Feb
NameKovacs Shane William Charles
RoleCH. OPERATING & FINANCIAL OFF.
TransactionAcquired
TypeA-Award
Shares320000
Date28 Feb
NameBohen Sean
RolePRESIDENT AND CEO
TransactionAcquired
TypeA-Award
Shares650000
DateNameRoleTransactionTypeShares
28 FebMyles David C.CH. DISCOV. & NON-CLIN DEV OFFAcquiredA-Award205000
28 FebZojwalla NaseemCHIEF MEDICAL OFFICERAcquiredA-Award205000
28 FebMitchell ShawnteCHIEF LEGAL OFFICERAcquiredA-Award450000
28 FebKovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.AcquiredA-Award320000
28 FebBohen SeanPRESIDENT AND CEOAcquiredA-Award650000

Discover More

Streamlined Academy

Olema Pharmaceuticals, Inc.

NASDAQ

Market Cap.

312.75M

Avg. Volume

970.79K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Olema Pharmaceuticals, Inc. News

Olema Pharmaceuticals, Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Olema Pharmaceuticals, Inc. Earnings & Revenue

Olema Pharmaceuticals, Inc. Income

Olema Pharmaceuticals, Inc. Balance Sheet

Olema Pharmaceuticals, Inc. Cash Flow

Olema Pharmaceuticals, Inc. Financials Over Time

Olema Pharmaceuticals, Inc. Executives

NameRole
Dr. Sean P. Bohen M.D., Ph.D.President, Chief Executive Officer & Director
Mr. Shane William Charles Kovacs M.B.A.Chief Operating & Financial Officer
Dr. Naseem Zojwalla M.D.Chief Medical Officer
Dr. David C. Myles Ph.D.Chief Discovery & Non-Clinical Development Officer
Ms. Julie DexterSenior Vice President & Head of People
NameRoleGenderDate of BirthPay
Dr. Sean P. Bohen M.D., Ph.D.President, Chief Executive Officer & Director19671.12M
Mr. Shane William Charles Kovacs M.B.A.Chief Operating & Financial OfficerMale1974845.37K
Dr. Naseem Zojwalla M.D.Chief Medical Officer1973777.97K
Dr. David C. Myles Ph.D.Chief Discovery & Non-Clinical Development Officer1963200K
Ms. Julie DexterSenior Vice President & Head of PeopleFemale

--

Olema Pharmaceuticals, Inc. Insider Trades

Date28 Feb
NameMyles David C.
RoleCH. DISCOV. & NON-CLIN DEV OFF
TransactionAcquired
TypeA-Award
Shares205000
Date28 Feb
NameZojwalla Naseem
RoleCHIEF MEDICAL OFFICER
TransactionAcquired
TypeA-Award
Shares205000
Date28 Feb
NameMitchell Shawnte
RoleCHIEF LEGAL OFFICER
TransactionAcquired
TypeA-Award
Shares450000
Date28 Feb
NameKovacs Shane William Charles
RoleCH. OPERATING & FINANCIAL OFF.
TransactionAcquired
TypeA-Award
Shares320000
Date28 Feb
NameBohen Sean
RolePRESIDENT AND CEO
TransactionAcquired
TypeA-Award
Shares650000
DateNameRoleTransactionTypeShares
28 FebMyles David C.CH. DISCOV. & NON-CLIN DEV OFFAcquiredA-Award205000
28 FebZojwalla NaseemCHIEF MEDICAL OFFICERAcquiredA-Award205000
28 FebMitchell ShawnteCHIEF LEGAL OFFICERAcquiredA-Award450000
28 FebKovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.AcquiredA-Award320000
28 FebBohen SeanPRESIDENT AND CEOAcquiredA-Award650000

Streamlined Academy

Website screenshot
HealthcareBiotechnology
olema.com

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. Financials

Table Compare

Compare OLMA metrics with:

   

Earnings & Growth

OLMA

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

OLMA

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

OLMA

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

OLMA

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Olema Pharmaceuticals, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioBuy
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)